Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions and Cardiovascular Atherosclerosis.
Status:
Recruiting
Trial end date:
2025-01-26
Target enrollment:
Participant gender:
Summary
Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo
imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron
Emission Tomography (PET) in patients with oncological lesions in need of non-surgical
therapy and patients with cardiovascular atherosclerosis.